These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20937788)

  • 21. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.
    Ordway DJ; Shanley CA; Caraway ML; Orme EA; Bucy DS; Hascall-Dove L; Henao-Tamayo M; Harton MR; Shang S; Ackart D; Kraft SL; Lenaerts AJ; Basaraba RJ; Orme IM
    Antimicrob Agents Chemother; 2010 May; 54(5):1820-33. PubMed ID: 20160055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteriologic basis of short-course chemotherapy for tuberculosis.
    Grosset J
    Clin Chest Med; 1980 May; 1(2):231-41. PubMed ID: 6794976
    [No Abstract]   [Full Text] [Related]  

  • 28. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.
    Hu Y; Mangan JA; Dhillon J; Sole KM; Mitchison DA; Butcher PD; Coates AR
    J Bacteriol; 2000 Nov; 182(22):6358-65. PubMed ID: 11053379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
    J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
    Dhillon J; Dickinson JM; Sole K; Mitchison DA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuberculosis of the tonsil simulating a cancer.
    Sellami M; Mnejja M; Charfi S; Ghorbel A
    Lancet Infect Dis; 2017 Dec; 17(12):1317. PubMed ID: 29173890
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
    Lenaerts AM; Chase SE; Chmielewski AJ; Cynamon MH
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2356-60. PubMed ID: 10508006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.
    Rustomjee R; Diacon AH; Allen J; Venter A; Reddy C; Patientia RF; Mthiyane TC; De Marez T; van Heeswijk R; Kerstens R; Koul A; De Beule K; Donald PR; McNeeley DF
    Antimicrob Agents Chemother; 2008 Aug; 52(8):2831-5. PubMed ID: 18505852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
    Lounis N; Gevers T; Van Den Berg J; Andries K
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3568-72. PubMed ID: 18644960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].
    Lounis N; Guillemont J; Veziris N; Koul A; Jarlier V; Andries K
    Med Mal Infect; 2010 Jul; 40(7):383-90. PubMed ID: 19954909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
    Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.
    Reddy VM; Einck L; Andries K; Nacy CA
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2840-6. PubMed ID: 20385864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.